Rezolute, Inc. (RZLT)
$3.97-$0.18 (-4.34%) Latest session
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Tax withholding / forfeiture | 4 | 16,395 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
24 Form 4 filings on record, the earliest from Dec 10, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sunil Ratilal Karnawat - Officer | Tax withholding / forfeiture | Common Shares | 2,267 | $4.50 | $10K | |
| Brian Kenneth Roberts - Officer | Tax withholding / forfeiture | Common Shares | 3,062 | $4.99 | $15K | |
| Nevan C. Elam - Officer | Tax withholding / forfeiture | Common Shares | 8,004 | $4.99 | $40K | |
| Daron Evans - Officer | Tax withholding / forfeiture | Common Shares | 3,062 | $4.99 | $15K | |
| Daron Evans - Officer | Open-market purchase | Common Shares | 10,000 | $2.85 | $29K | |
| Brian Kenneth Roberts - Officer | Tax withholding / forfeiture | Common Shares | 11,439 | $2.99 | $34K | |
| Daron Evans - Officer | Tax withholding / forfeiture | Common Shares | 11,438 | $2.99 | $34K | |
| Nevan C. Elam - Officer | Tax withholding / forfeiture | Common Shares | 27,618 | $2.99 | $83K | |
| Wladimir Hogenhuis | Open-market purchase | Common Shares | 5,650 | $1.69 | $10K | |
| Brian Kenneth Roberts - Officer | Open-market purchase | Common Shares | 28,000 | $1.70 | $48K | |
| Gil M. Labrucherie | Grant or award | Common Shares | 21,000 | $0.00 | - | |
| Gil M. Labrucherie | Grant or award | Director Stock Option (Right to Buy) | 12,000 | $0.00 | - | |
| Philippe Fauchet | Grant or award | Common Shares | 21,000 | $0.00 | - | |
| Philippe Fauchet | Grant or award | Director Stock Option (Right to Buy) | 12,000 | $0.00 | - | |
| Young-Jin Kim | Grant or award | Common Shares | 21,000 | $0.00 | - | |
| Young-Jin Kim | Grant or award | Director Stock Option (Right to Buy) | 12,000 | $0.00 | - | |
| Erik Harris | Grant or award | Common Shares | 21,000 | $0.00 | - | |
| Erik Harris | Grant or award | Director Stock Option (Right to Buy) | 12,000 | $0.00 | - | |
| Wladimir Hogenhuis | Grant or award | Common Shares | 21,000 | $0.00 | - | |
| Wladimir Hogenhuis | Grant or award | Director Stock Option (Right to Buy) | 12,000 | $0.00 | - | |
| Nerissa Kreher | Grant or award | Common Shares | 21,000 | $0.00 | - | |
| Nerissa Kreher | Grant or award | Director Stock Option (Right to Buy) | 12,000 | $0.00 | - | |
| Nevan C. Elam - Officer | Grant or award | Common Shares | 317,000 | $0.00 | - | |
| Nevan C. Elam - Officer | Grant or award | Employee Stock Option (Right to Buy) | 186,000 | $0.00 | - | |
| Daron Evans - Officer | Grant or award | Common Shares | 107,000 | $0.00 | - | |
| Daron Evans - Officer | Grant or award | Employee Stock Option (Right to Buy) | 63,000 | $0.00 | - | |
| Sunil Ratilal Karnawat - Officer | Grant or award | Common Shares | 32,000 | $0.00 | - | |
| Sunil Ratilal Karnawat - Officer | Grant or award | Employee Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Brian Kenneth Roberts - Officer | Grant or award | Common Shares | 123,000 | $0.00 | - | |
| Sunil Ratilal Karnawat - Officer | Grant or award | Common Shares | 25,000 | $0.00 | - | |
| Sunil Ratilal Karnawat - Officer | Grant or award | Employee Stock Option (Right to Buy) | 275,000 | $0.00 | - | |
| Daron Evans - Officer | Open-market purchase | Common Shares | 10,000 | $4.29 | $43K | |
| Daron Evans - Officer | Open-market purchase | Common Shares | 9,000 | $4.60 | $41K | |
| Daron Evans - Officer | Open-market purchase | Common Shares | 10,549 | $5.04 | $53K |
Rezolute, Inc. (RZLT) had 4 insider filings in the last 90 days, with the most recent on 2026-09-03. The full record for RZLT runs to 24 Form 4 filings, the earliest from 2024-12-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RZLT were filed in the last 90 days. 6 purchases are on record for this company.
No insider sales of RZLT were filed in the last 90 days.
This page tracks RZLT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RZLT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
